| Modified mRNA vaccines protect against Zika virus infection JM Richner, S Himansu, KA Dowd, SL Butler, V Salazar, JM Fox, ... Cell 168 (6), 1114-1125. e10, 2017 | 879 | 2017 |
| Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses K Bahl, JJ Senn, O Yuzhakov, A Bulychev, LA Brito, KJ Hassett, ME Laska, ... Molecular Therapy 25 (6), 1316-1327, 2017 | 631 | 2017 |
| Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines KJ Hassett, KE Benenato, E Jacquinet, A Lee, A Woods, O Yuzhakov, ... Molecular Therapy-Nucleic Acids 15, 1-11, 2019 | 578 | 2019 |
| In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates K Musunuru, AC Chadwick, T Mizoguchi, SP Garcia, JE DeNizio, ... Nature 593 (7859), 429-434, 2021 | 481 | 2021 |
| Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry M Westby, C Smith-Burchnell, J Mori, M Lewis, M Mosley, M Stockdale, ... Journal of virology 81 (5), 2359-2371, 2007 | 454 | 2007 |
| Directed evolution of adenine base editors with increased activity and therapeutic application NM Gaudelli, DK Lam, HA Rees, NM Solá-Esteves, LA Barrera, DA Born, ... Nature biotechnology 38 (7), 892-900, 2020 | 420 | 2020 |
| mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials RA Feldman, R Fuhr, I Smolenov, AM Ribeiro, L Panther, M Watson, ... Vaccine 37 (25), 3326-3334, 2019 | 397 | 2019 |
| HIV capsid is a tractable target for small molecule therapeutic intervention WS Blair, C Pickford, SL Irving, DG Brown, M Anderson, R Bazin, J Cao, ... PLoS pathogens 6 (12), e1001220, 2010 | 306 | 2010 |
| Efficient targeting and activation of antigen-presenting cells in vivo after modified mRNA vaccine administration in rhesus macaques F Liang, G Lindgren, A Lin, EA Thompson, S Ols, J Röhss, S John, ... Molecular Therapy 25 (12), 2635-2647, 2017 | 297 | 2017 |
| Vaccine mediated protection against Zika virus-induced congenital disease JM Richner, BW Jagger, C Shan, CR Fontes, KA Dowd, B Cao, ... Cell 170 (2), 273-283. e12, 2017 | 274 | 2017 |
| Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity S John, O Yuzhakov, A Woods, J Deterling, K Hassett, CA Shaw, ... Vaccine 36 (12), 1689-1699, 2018 | 211 | 2018 |
| A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection N Kose, JM Fox, G Sapparapu, R Bombardi, RN Tennekoon, AD De Silva, ... Science immunology 4 (35), eaaw6647, 2019 | 188 | 2019 |
| Nucleic acid vaccines G Ciaramella, A Bouchon, EYC Huang US Patent 10,022,435, 2018 | 164 | 2018 |
| Cytosine base editors with minimized unguided DNA and RNA off-target events and high on-target activity Y Yu, TC Leete, DA Born, L Young, LA Barrera, SJ Lee, HA Rees, ... Nature Communications 11 (1), 2052, 2020 | 163 | 2020 |
| Nucleic acid vaccines G Ciaramella, A Bouchon, EYC Huang US Patent 9,872,900, 2018 | 162 | 2018 |
| Modified mRNA-based vaccines elicit robust immune responses and protect guinea pigs from Ebola virus disease M Meyer, E Huang, O Yuzhakov, P Ramanathan, G Ciaramella, ... The Journal of infectious diseases 217 (3), 451-455, 2018 | 156 | 2018 |
| Induction of robust B cell responses after influenza mRNA vaccination is accompanied by circulating hemagglutinin-specific ICOS+ PD-1+ CXCR3+ T follicular helper cells G Lindgren, S Ols, F Liang, EA Thompson, A Lin, F Hellgren, K Bahl, ... Frontiers in immunology 8, 1539, 2017 | 135 | 2017 |
| Modified mRNA/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection AS Espeseth, PJ Cejas, MP Citron, D Wang, DJ DiStefano, C Callahan, ... npj Vaccines 5 (1), 16, 2020 | 124 | 2020 |
| Characterization and mutational analysis of the helicase and NTPase activities of hepatitis C virus full-length NS3 protein. AD Wardell, W Errington, G Ciaramella, J Merson, MJ McGarvey Journal of General Virology 80 (3), 701-709, 1999 | 120 | 1999 |
| Uptake, efficacy, and systemic distribution of naked, inhaled short interfering RNA (siRNA) and locked nucleic acid (LNA) antisense SA Moschos, M Frick, B Taylor, P Turnpenny, H Graves, KG Spink, ... Molecular Therapy 19 (12), 2163-2168, 2011 | 105 | 2011 |
